Circadian variation in drug metabolism and tissue sensitivity to drugs affects their activity and toxicity. A growing body of data suggests that therapy may be improved and toxicity reduced by administering antineoplastic agents at carefully selected times of the day. Here I briefly review molecular, cellular, and organismic time-keeping mechanisms as well as cytokinetic, pharmacokinetic, and pharmacodynamic data, which support the predictable and exploitable nonlinear dynamic relation between dose and effect that occurs each day.
Background
In 1972, a paper in Science reported that the arrangement within a given day of 3-h doses of cytosine arabinoside (Ara-C) had a profound effect on the cure of mice inoculated with L1210 leukemia cells (1)1. This study was built on extensive prior work and demonstrated that all Ara-C toxicities are markedly dependent on the time in the day/night cycle at which the drug is adminiStered (2). Together, the experiments showed unequivocally that, in mice, the timing of Ara-C administration predictably modulates its therapeutic irldex. Surprisingly, nearly 20 years later, this simple hypothesis has stifi not been extended to clinical trials for human leukemia, even though the mainstay treatment for the most common deadly acute leukemias has remained Ara-C, used at higher and higher dose intensity with greater and greater toxicity (3). In the meantime, it has been shown that all anthracyclines, which are generally coupled with Ara-C to treat the nonlymphocytic leukemias, also exhibit a pronounced circadian time dependency in their pharmacology, toxicology, and efficacy in mice and humans
(4-6).
Furthermore, many combination chemotherapy studies, done in follow-up to the initial Ara-C study, have demonstrated that the addition of a second or third drug to the regimen seldom interferes with the enhancement in therapeutic index that results from circadian optimization of each drug (7) . .1 j Figure   1 demonstrates some of the advantages of optimal circadian shaping of FUDR continuous infusion in tumor-bearing rats and in patients with metastatic renal cell carcinoma.
5-FU Chronopharmacokinetics
The Each member of these groups of rats and cancer patients was randomized to receive the Identicaldose of Infusional FUDR chemotherapy. In one group, rats or patients received continuous constant-rate infusion (U) or Infusions peaking late in each daily activity span and early In the usualdailysleepspan (s). In the circadian-based schedules, 68% of each days dose was given during these 6 h, 15% in each abutting daily quadrat* and 2% of each daily dose near daily arising.
In the rat, FUDR toxicity was affected by the circadlan shape of the Infusion (data not shown) and tumor shrinkage was enhanced by optimalcircadlanFUDR infusion shape. In 30 cancerpatients, randomly assignedto one or the otherInfusionpattern,toxicity was markedlydiminishedby optimaltiming(datanotshown).
This circadlan toxicity dependence resulted In8 times more frequent treatment delays of 1 week and 6 times morefrequent dose reductionsof 20% than when constant-rate Infusionwas used. This also resulted Inbeing ableto safelyIncrease the average dose Intensity by circadianInfusion byatleast 50% (from 0.4 to 
Continuous Fluoropyrimidine Constant-Rate Infusion
The top panel of Figure 2 In contrast, the activity of DHD, which catabolizes 5-FU, is highly rhythmic throughout each day. The waning of DPD activity during the daily activity span results in an accumulation of 5-FlY during the day. The endogenous circadian increase in DPD activity during the evening results in daily decreases of 5-FU concentrations during the evening.
In other words, the bioavailability of 5-FlY waxes and wanes during the day. During FUDR infusion, the near constant thymidine phosphotylase activity does not modify the effect of rhythmic DPD activity on the rhythmicity of 5-FU concentrations. The effective concentration of fluoropyrimidine species is therefore higher during the morning hours, when less FlY has been removed.
Rhythmic
FUDR anabolism. in an even greater amplitude in daily FDUMP availability. The middle panel of Figure 2 demonstrates the effects that these circadian patterns of enzyme activity have on the concentrations of fluoropyrimidine; it also depicts the theoretical effect this time structure may have on intracellular FDUMP concentration during a constant-rate continuous infusion of fluoropyrimidine.
Rhythmic gut cytokinetics.
The amount of target enzyme (TS) activity covaries with the DNA synthetic capacity of the tissue. TS is, in fact, in critical supply only during the process of DNA synthesis.
The bottom panel of Figure 2 demonstrates the experimentally determined circadian pattern of DNA synthetic activity in the two human tissues that are most prominently damaged by fluoropyrimidines: gut mucosa and bone marrow; indeed, DNA synthetic activity in these tissues cycles prominently within each day. Much more DNA synthesis occurs in the morning, during the first half of the daily activity span. The daily timing of high DNA synthesis activity in both of these critical tissues occurs when DPD activity is lowest and thymidine kinase activity is highest, coinciding with the time of day of the highest DNA synthesis and the time associated with the greatest need for TS activity.
These temporal coincidences mean that a zero-order infusion of FU or FUDR can be predicted to result in a high-amplitude circadian rhythm in the active intracellular TS blocker, FDtJMP. However, this remains to be proven experimentally. This theoretical peak in daily FDUMP availability would happen at the time associated with the highest daily synthesis of DNA in gut and bone marrow and therefore the time of the greatest need for TS activity in gut and bone marrow and the time of highest tissue susceptibility.
The time-of-day-dependent toxicology predicted by the arrangement in time of these critical enzyme activities has already been clearly demonstrated in mice, rats, and humans, as discussed earlier. Taken together, the preclinical and clinical data defining optimum timings of 5-FIT and FUDR administration are compelling. The time-dependent differences in toxic-therapeutic ratios of these drugs are substantial and we are now beginning to understand the biochemical and cellular mechanisms that contribute to these differences.
Implications for Clinical Trials with Cytotoxic Drugs
A complete understanding of circadian control mechanisms should not be a prerequisite for incorporation of these ideas into clinical trials. Clearly many advances in the chemotherapeutic control of human malignancy have been gained without a sophisticated understanding of the mechanisms of action of each drug in effective chemotherapy regimens. In my view, our present knowledge of circadian pharmacodynainics is sufficient to enable us not only to optimize the effectiveness of the chemotherapeutic agents currently in use but perhaps also to expand the repertoire of effective anticancer treatments. It is daunting to realize that scores of anticancer drugs discovered in murine screens and subsequently rejected in phase I trials because of unacceptably high toxicity to humans were recommended for clinical study on the basis of murine toxicology and efficacy studies performed during the animals' usual sleep span and were later rejected clinically on the basis of studies routinely performed during the activity span of the cancer patients tested.
The Future
As newer therapeutic approaches are developed with growth factors and other genetically engineered proteins, temporal questions become ever more important. We have already found, for example, that (a) the LDso for tumor necrosis factor varies by the magnitude of one logarithm and its curative efficacy varies sevenfold, depending on the time of day it is administered ( 
